The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

With two maintenance doses a year, Leqvio is the first and only FDA- approved small interfering RNA therapy for LDL-C reduction 1 Leqvio provides effective and sustained LDL-C reduction of up to ...

Leqvio is the first and only small interfering RNA (siRNA) therapy to lower LDL-C and is administered with two doses a year*. Results were presented at the American Heart Association (AHA ...

Leqvio is the first and only small interfering RNA (siRNA) therapy to lower LDL-C. It is approved in over 90 countries, including the U.S., EU, Japan and China1,5,6.

For Leqvio’s launch, Novartis is taking a population health-based approach at 200 large U.S. healthcare systems in an effort to identify eligible patients. Among them, at least 50 systems have ...

Please click here for LEQVIO full Prescribing Information. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 ©2024 Novartis 6/24 FA-11211322 ...